Janux Therapeutics, INC Form 4 insider transactions

Janux Therapeutics, Inc. Director Winston Kung has reported an increase in his beneficial ownership through the grant of restricted stock units and stock options, aligning his interests with shareholders.

Janeen Noel Doyle, Chief Corporate and Business Development Officer of Janux Therapeutics, Inc., was granted 44,000 restricted stock units and options to purchase 154,000 shares of common stock.

Andrew Hollman Meyer, Chief Business Officer of Janux Therapeutics, reports the acquisition and disposal of common stock and stock options on May 1, 2025.

Andrew Hollman Meyer, Chief Business Officer of Janux Therapeutics, reports the exercise of stock options and subsequent sale of shares under a pre-arranged trading plan.

RA Capital Management and related entities have increased their holdings in Janux Therapeutics through a series of open market purchases.

Andrew Hollman Meyer, Chief Business Officer of Janux Therapeutics, sold shares of common stock on March 3, 2025, under a pre-arranged 10b5-1 trading plan.

Andrew Hollman Meyer, Chief Business Officer of Janux Therapeutics, sold shares of common stock on February 3, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Janux Therapeutics CEO, David Alan Campbell, sold 5,000 shares of common stock at an average price of $60.0008 per share under a pre-arranged 10b5-1 trading plan.

Janux Therapeutics' Chief Medical Officer, Zachariah McIver, was granted 91,000 stock options and 26,000 restricted stock units on January 2, 2025.

Janux Therapeutics' Chief Technical Officer, Charles M. Winter, acquired 23,000 restricted stock units and 80,500 stock options, while also reporting existing share holdings.

Janux Therapeutics CEO, David Alan Campbell, received stock options and restricted stock units as part of his compensation package.

Byron Robinson, Chief Strategy Officer at Janux Therapeutics, was granted 28,000 restricted stock units and stock options for 98,000 shares.

Janux Therapeutics' Chief Scientific Officer, Thomas DiRaimondo, was granted stock options and restricted stock units on January 2, 2025, according to a recent SEC filing.

Maria Dobek, Vice President of Accounting at Janux Therapeutics, was granted stock options and restricted stock units, increasing her beneficial ownership in the company.

Andrew Hollman Meyer, Chief Business Officer of Janux Therapeutics, sold shares of common stock and received stock options on January 2, 2025, according to a Form 4 filing with the SEC.

Janux Therapeutics CEO, David Alan Campbell, sold 25,000 shares of common stock at a weighted average price of $56.1922 per share, as part of a pre-arranged 10b5-1 trading plan.

Andrew Hollman Meyer, Chief Business Officer of Janux Therapeutics, exercised stock options on December 19, 2024, acquiring 9,881 shares of common stock.

Janux Therapeutics CEO, David Alan Campbell, sold 15,000 shares of common stock at $67 per share on December 3, 2024, under a pre-arranged 10b5-1 trading plan.

Janux Therapeutics CEO, David Alan Campbell, sold a total of 25,000 shares of common stock on November 25, 2024, under a pre-arranged 10b5-1 trading plan.

Sheila Gujrathi, a director at Janux Therapeutics, received 4,611 shares of common stock through a pro rata, in-kind distribution on November 5, 2024.

Director Vickie L Capps receives 2,305 shares of Janux Therapeutics common stock through an in-kind distribution from ABV SPV I GP LLC.

Janux Therapeutics CEO David Campbell sold a portion of his common stock holdings on October 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Jay Lichter reports multiple transactions involving Janux Therapeutics common stock and stock options on September 13, 2024.

RA Capital Management and related entities acquired 1,200,000 shares of Janux Therapeutics at $44.75 per share in a private transaction, increasing their beneficial ownership.

Avalon Ventures XI, L.P., Avalon BioVentures I, LP, Avalon BioVentures SPV I, L.P., and Jay Lichter report sales and option exercises of Janux Therapeutics, Inc. stock between October 16 and October 18, 2024.

Avalon Ventures XI, L.P. and related entities, including Jay Lichter, reported the sale of Janux Therapeutics (JANX) common stock and the exercise of stock options across multiple transactions in late September 2024.

Andrew Hollman Meyer, Chief Business Officer of Janux Therapeutics, sold 50,000 shares of common stock on September 27, 2024, after exercising stock options.

Thomas DiRaimondo, Chief Scientific Officer of Janux Therapeutics, sold a portion of his holdings in the company's common stock on September 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Janux Therapeutics' CEO, David Alan Campbell, executed multiple sales of common stock on September 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Avalon Ventures XI, L.P., along with related entities, sold shares of Janux Therapeutics (JANX) between September 10 and September 12, 2024.